Lixte Biotechnology (LIXT) Fundamental Analysis: Revenue, Earnings & Valuation

5.08 / 10

Netural

Fundamental analysis scores 5.08/10, also neutral. Strengths include a high PB‑ROE (weight 0.29), strong cash‑to‑market and inventory turnover. Weak points are negative Asset‑MV and Revenue‑MV, low gross margin and adverse income‑tax ratio. Overall, fundamentals are average with selective positives.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score1/3

Weight14.02%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value78.03

Score3/3

Weight3.62%

1M Return1.54%

Inventory turnover ratio

Value47.95

Score3/3

Weight18.60%

1M Return6.74%

Gross profit margin (%)

Value36.92

Score1/3

Weight-1.32%

1M Return-0.63%

PB-ROE

Value1.42

Score3/3

Weight29.17%

1M Return9.74%

Income tax / Total profit (%)

Value-5.45

Score1/3

Weight-1.07%

1M Return-0.50%

Fixed assets turnover ratio

Value7895.57

Score3/3

Weight2.40%

1M Return1.06%

Cost of sales ratio (%)

Value70.31

Score3/3

Weight10.76%

1M Return4.32%

Asset-MV

Value-0.49

Score0/3

Weight7.30%

1M Return2.69%

Cash-MV

Value-0.09

Score2/3

Weight16.52%

1M Return5.94%

Is LIXT undervalued or overvalued?

LIXT scores 5.08/10 on fundamentals and holds a Fair valuation at present. Backed by its -103.13% ROE, 0.00% net margin, -5.86 P/E ratio, 3.25 P/B ratio, and 20.75% earnings growth, these metrics solidify its Netural investment rating.